benzoxazoles has been researched along with Hyperlipidemias in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 3 (37.50) | 2.80 |
| Authors | Studies |
|---|---|
| Fujikawa, T; Sogabe, Y | 1 |
| Kusunoki, M; Miyata, T; Oshida, Y; Sakazaki, T; Tsutsumi, K | 1 |
| Hoshino, T; Ishizuka, K; Kitagawa, K; Seki, M; Toi, S | 1 |
| Han, SI; Matsuzaka, T; Nakagawa, Y; Satoh, A; Sekiya, M; Shimano, H; Takei, K; Wang, Y | 1 |
| Blair, HA | 1 |
| Fujioka, Y | 1 |
| Li, TB; Liu, B; Liu, WQ; Luo, XJ; Ma, QL; Peng, J; Wu, Y; Xiong, XM; Zhang, JJ | 1 |
| Corjay, MH; Diamond, SM; Kearney, MA; Munzer, DA; Stoltenborg, JK | 1 |
1 review(s) available for benzoxazoles and Hyperlipidemias
| Article | Year |
|---|---|
Pemafibrate: First Global Approval.
Topics: Benzoxazoles; Butyrates; Cholesterol, HDL; Drug Approval; Humans; Hyperlipidemias; Lipid Metabolism; Lipoproteins, HDL; PPAR alpha; Protein Binding | 2017 |
7 other study(ies) available for benzoxazoles and Hyperlipidemias
| Article | Year |
|---|---|
Lipid Metabolic Disorder with Varied Clinical Manifestations.
Topics: Adult; Benzoxazoles; Blood Glucose; Butyrates; Diabetes Mellitus, Type 2; Diet, Fat-Restricted; Humans; Hyperlipidemias; Hypertriglyceridemia; Hypolipidemic Agents; Insulin; Lipid Metabolism Disorders; Male; Retinal Diseases; Xanthomatosis | 2022 |
The Effects of Pemafibrate in Japanese Patients with Type 2 Diabetes Receiving HMG-CoA Reductase Inhibitors.
Topics: Adult; Aged; Benzoxazoles; Butyrates; Cholesterol, HDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Japan; Male; Middle Aged; Treatment Outcome; Triglycerides | 2021 |
Effects of Pemafibrate in Patients with Stroke and Hypertriglyceridemia: Baseline Cerebral Artery Diseases and 3-Month Laboratory Outcomes.
Topics: Atherosclerosis; Benzoxazoles; Butyrates; Cerebral Arterial Diseases; Humans; Hyperlipidemias; Hypertriglyceridemia; Male; Middle Aged; Prospective Studies; Stroke; Triglycerides | 2022 |
Effects of K-877, a novel selective PPARα modulator, on small intestine contribute to the amelioration of hyperlipidemia in low-density lipoprotein receptor knockout mice.
Topics: Animals; Atherosclerosis; Benzoxazoles; Butyrates; Cholesterol; Disease Models, Animal; Fatty Acids; Gene Expression; Gene Knockout Techniques; Hyperlipidemias; Intestinal Absorption; Intestine, Small; Lipid Metabolism; Liver; Male; Mice, Inbred C57BL; Mice, Knockout; Molecular Targeted Therapy; Oxidation-Reduction; PPAR alpha; Receptors, LDL | 2017 |
Effects of a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator K-877 (Pemafibrate) on Postprandial hyperlipidemia.
Topics: Animals; Benzoxazoles; Butyrates; Hyperlipidemias; Hypertriglyceridemia; Mice; PPAR alpha | 2018 |
Involvement of NADPH oxidases and non-muscle myosin light chain in senescence of endothelial progenitor cells in hyperlipidemia.
Topics: Animals; Azepines; Benzoxazoles; Cellular Senescence; Endothelial Progenitor Cells; Hyperlipidemias; Lipids; Male; Myosin Light Chains; Myosin-Light-Chain Kinase; NADPH Oxidases; Naphthalenes; Phosphorylation; Rats, Sprague-Dawley; Reactive Oxygen Species; RNA, Messenger; RNA, Small Interfering; Triazoles | 2016 |
Antiproliferative gene BTG1 is highly expressed in apoptotic cells in macrophage-rich areas of advanced lesions in Watanabe heritable hyperlipidemic rabbit and human.
Topics: 3T3 Cells; Animals; Apoptosis; Arteriosclerosis; Benzoxazoles; Cell Division; Cell Line, Transformed; DNA Fragmentation; Fluorescent Dyes; Humans; Hyperlipidemias; Immunohistochemistry; Intercellular Adhesion Molecule-1; Macrophages; Mice; Neoplasm Proteins; Quinolinium Compounds; Rabbits; Recombinant Proteins; RNA, Messenger; Transcription, Genetic; Transfection | 1998 |